Care Partner vs. Caregiver: Why Language Matters in Lymphoma Support When a loved one is diagnosed with lymphoma, the individuals who support them play a crucial role in their journey. Historically, these individuals have been referred to as “caregivers,” but…
The U.S. Food and Drug Administration (FDA) Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or Refractory Large B-cell Lymphoma February 12, 2025 – On February 12, 2025, the U.S. Food and Drug Administration (FDA) announced it has approved…
The U.S. Food and Drug Administration (FDA) Approves Acalabrutinib (CALQUENCE) for Mantle Cell Lymphoma January 16, 2025 – On January 16, 2025, the U.S. Food and Drug Administration (FDA) announced it has approved acalabrutinib (CALQUENCE, AstraZeneca) with bendamustine and rituximab…
Where Are They Now? John Pagel, MD, PhD When did you become interested in the study of medicine? In lymphoma specifically? When I was a kid, I was interested in two things: sports and science! Some of my earliest memories…
Where Are They Now? Jamie Flerlage, MD, MS When did you become interested in the study of medicine? In lymphoma specifically? After realizing in high school that only 1% of astronauts went to space, I shifted my love for science…
On June 26, 2024, the U.S. Food and Drug Administration (FDA) announced it has granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.) for adults with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines…
On May 30, 2024, the U.S. Food and Drug Administration (FDA) announced it has approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with relapsed or refractory mantle cell lymphoma (MCL) who have received two or more prior lines of…
On May 15, 2024, the U.S. Food and Drug Administration (FDA) announced it has approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic…
On March 7, 2024, the U.S. Food and Drug Administration (FDA) announced it has approved Bruton tyrosine kinase inhibitor (BTKi), zanubrutinib (Brukinsa, BeiGene USA, Inc.) with obinutuzumab for the treatment of adult patients with relapsed/refractory follicular lymphoma (FL) after two…